Tyrosine kinase inhibitors for radioiodine refractory differentiated thyroid cancer: A systematic review and meta-analysis.
Jiayi YuZheran LiuYonglin SuXing-Chen PengYuping XiePublished in: Clinical endocrinology (2024)
The results of this meta-analysis suggest that targeted therapy with TKIs may be beneficial for patients with radioiodine-refractory advanced or metastatic differentiated thyroid cancer. Among the TKIs analyzed, lenvatinib appeared to be the most effective at improving PFS, although it also had the highest incidence of AEs. Further research through direct randomized controlled trials is needed to determine the optimal choice of TKI for treating patients with RAIR-DTC. This study is beneficial for formulating patients' treatment plans and guides clinicians' decision-making.
Keyphrases
- decision making
- systematic review
- end stage renal disease
- randomized controlled trial
- ejection fraction
- newly diagnosed
- small cell lung cancer
- squamous cell carcinoma
- meta analyses
- peritoneal dialysis
- prognostic factors
- risk factors
- palliative care
- chronic myeloid leukemia
- tyrosine kinase
- clinical trial
- health insurance
- patient reported outcomes
- combination therapy
- case control
- replacement therapy